Literature DB >> 22617225

Models for disease progression: new approaches and uses.

D R Mould1.   

Abstract

Disease-progression models are useful tools in drug development. They increase the information obtained from clinical trials, improve study designs, and allow in silico evaluations of new treatment combinations and dose regimens. Disease-progression modeling can save time and strengthen "go/no-go" criteria. The use of meta-based modeling and the linking of disease progression to discrete clinical end points have improved the utility of this valuable approach. This article provides an overview of disease-progression evaluations using these new approaches.

Mesh:

Year:  2012        PMID: 22617225     DOI: 10.1038/clpt.2012.53

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

1.  Doctor AI: Predicting Clinical Events via Recurrent Neural Networks.

Authors:  Edward Choi; Mohammad Taha Bahadori; Andy Schuetz; Walter F Stewart; Jimeng Sun
Journal:  JMLR Workshop Conf Proc       Date:  2016-12-10

Review 2.  Novel methods and technologies for 21st-century clinical trials: a review.

Authors:  E Ray Dorsey; Charles Venuto; Vinayak Venkataraman; Denzil A Harris; Karl Kieburtz
Journal:  JAMA Neurol       Date:  2015-05       Impact factor: 18.302

3.  Disease Progression Modeling: Key Concepts and Recent Developments.

Authors:  Sarah F Cook; Robert R Bies
Journal:  Curr Pharmacol Rep       Date:  2016-08-15

4.  Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia.

Authors:  Mohamed Elmeliegy; Jason Den Haese; Chetasi Talati; Meir Wetzler; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2020-08-03       Impact factor: 3.333

5.  Toward a robust tool for pharmacokinetic-based personalization of treatment with tacrolimus in solid organ transplantation: A model-based meta-analysis approach.

Authors:  Tom M Nanga; Thao T P Doan; Pierre Marquet; Flora T Musuamba
Journal:  Br J Clin Pharmacol       Date:  2019-12-17       Impact factor: 4.335

6.  Alzheimer's disease progression model based on integrated biomarkers and clinical measures.

Authors:  Yue Qiu; Liang Li; Tian-yan Zhou; Wei Lu
Journal:  Acta Pharmacol Sin       Date:  2014-08-04       Impact factor: 6.150

7.  Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.

Authors:  S F Marshall; R Burghaus; V Cosson; S Y A Cheung; M Chenel; O DellaPasqua; N Frey; B Hamrén; L Harnisch; F Ivanow; T Kerbusch; J Lippert; P A Milligan; S Rohou; A Staab; J L Steimer; C Tornøe; S A G Visser
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-03-14

8.  Modeling NSCLC progression: recent advances and opportunities available.

Authors:  Ahmed Abbas Suleiman; Lucia Nogova; Uwe Fuhr
Journal:  AAPS J       Date:  2013-02-13       Impact factor: 4.009

Review 9.  Multiscale Modeling in the Clinic: Drug Design and Development.

Authors:  Colleen E Clancy; Gary An; William R Cannon; Yaling Liu; Elebeoba E May; Peter Ortoleva; Aleksander S Popel; James P Sluka; Jing Su; Paolo Vicini; Xiaobo Zhou; David M Eckmann
Journal:  Ann Biomed Eng       Date:  2016-02-17       Impact factor: 3.934

10.  Genome-wide interrogation of longitudinal FEV1 in children with asthma.

Authors:  Kehua Wu; Eric R Gamazon; Hae Kyung Im; Paul Geeleher; Steven R White; Julian Solway; George L Clemmer; Scott T Weiss; Kelan G Tantisira; Nancy J Cox; Mark J Ratain; R Stephanie Huang
Journal:  Am J Respir Crit Care Med       Date:  2014-09-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.